利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.029 秒)

    Compositions and methods for the treatment of cancer
    3.
    发明申请
    Compositions and methods for the treatment of cancer 审中-公开
    用于治疗癌症的组合物和方法

    公开(公告)号：US20050148524A1

    公开(公告)日：2005-07-07

    申请号：US11074849

    申请日：2005-03-09

    申请人： Jerome Zeldis ,  Andrew Zeitlin ,  Sol Barer

    发明人： Jerome Zeldis ,  Andrew Zeitlin ,  Sol Barer

    IPC分类号： A61K45/00 ,  A61K31/454 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/7056 ,  A61K31/724 ,  A61P35/00 ,  A61P43/00 ,  A61K31/7052

    CPC分类号： A61K31/4745 ,  A61K31/454 ,  A61K31/47 ,  A61K31/7056 ,  A61K31/724 ,  A61K31/445 ,  A61K2300/00

    摘要： This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

    摘要翻译： 本发明涉及可用于治疗或预防癌症的沙利度胺和另一种抗癌药物的组合物。 优选的抗癌药物是拓扑异构酶抑制剂。 特定组合物包含沙利度胺或其药学上可接受的盐，溶剂合物或包合物和伊立替康。 本发明还涉及治疗或预防癌症的方法，其包括向需要这种治疗或预​​防的患者施用沙利度胺和另一种抗癌药物。 本发明还涉及减少或避免与化疗或放射治疗相关的不良副作用的方法，其包括向需要这种减少或避免的患者施用沙利度胺。

    Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
    4.
    发明申请
    Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system 审中-公开
    使用方法和包含选择性细胞因子抑制药物的组合物用于治疗和控制中枢神经系统疾病

    公开(公告)号：US20070190070A1

    公开(公告)日：2007-08-16

    申请号：US10590575

    申请日：2004-09-03

    申请人： Jerome Zeldis ,  Peter Schafer

    发明人： Jerome Zeldis ,  Peter Schafer

    IPC分类号： A61K31/4704 ,  A61K31/425 ,  A61K31/4035

    CPC分类号： A61K31/4035 ,  A61K31/425 ,  A61K31/4704

    摘要： Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

    摘要翻译： 公开了治疗，预防和/或控制中枢神经系统疾病如帕金森病，阿尔茨海默病，轻度认知障碍，亨廷顿舞蹈症，扁桃腺侧索硬化，抑郁症和有缺陷的长期记忆的方法和相关综合征。 具体方法包括单独或与第二活性成分组合施用选择性细胞因子抑制药物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药。 还公开了适用于本发明方法的药物组合物，单一单位剂型和试剂盒。

    Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
    5.
    发明申请
    Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases 审中-公开
    使用方法和包含选择性细胞因子抑制药物的组合物用于治疗和治疗骨髓增生性疾病

    公开(公告)号：US20060165649A1

    公开(公告)日：2006-07-27

    申请号：US10534324

    申请日：2003-04-13

    申请人： Jerome Zeldis

    发明人： Jerome Zeldis

    IPC分类号： A61K38/19 ,  A61K38/21 ,  A61K35/14 ,  A61K31/704 ,  A61K31/724 ,  A61K31/573

    CPC分类号： A61K38/212 ,  A61K31/573 ,  A61K31/704 ,  A61K31/724 ,  A61K2300/00

    摘要： Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

    摘要翻译： 公开了治疗，预防和/或治疗骨髓增生性疾病的方法。 具体方法包括单独或与第二活性剂组合施用选择性细胞因子抑制药物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药，和/或移植血液或细胞。 特别的第二活性剂能够抑制造血干细胞的过量产生或改善一种或多种MPD症状。 还公开了适用于本发明方法的药物组合物，单一单位剂型和试剂盒。

    Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
    7.
    发明申请
    Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders 失效
    用于预防和治疗动脉粥样硬化，再狭窄和相关疾病的方法和组合物

    公开(公告)号：US20060004054A1

    公开(公告)日：2006-01-05

    申请号：US11216950

    申请日：2005-08-30

    申请人： Jerome Zeldis

    发明人： Jerome Zeldis

    IPC分类号： A61K31/454 ,  A61K31/277

    CPC分类号： A61K31/445 ,  A61K9/0024 ,  A61K31/16 ,  A61K31/165 ,  A61K31/195 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/44 ,  A61K31/454

    摘要： Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor α(TNF-α) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.

    摘要翻译： 描述了用于预防和治疗所有形式的动脉粥样硬化的方法和组合物。 在本发明中使用诸如沙利度胺，其类似物，水解产物，代谢产物，衍生物和前体的化合物以及能够抑制肿瘤坏死因子α（TNF-α）的其它化合物的给药。 还公开了将假体装置（例如支架）与本发明的化合物一起涂覆以预防和/或治疗再狭窄。

    Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
    8.
    发明申请
    Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases 审中-公开
    使用免疫调节化合物治疗和治疗中枢神经系统疾病或疾病的方法和组合物

    公开(公告)号：US20050143344A1

    公开(公告)日：2005-06-30

    申请号：US11022075

    申请日：2004-12-23

    申请人： Jerome Zeldis ,  Herbert Faleck ,  Peter Schafer

    发明人： Jerome Zeldis ,  Herbert Faleck ,  Peter Schafer

    IPC分类号： A61K31/00 ,  A61K31/454 ,  A61K31/724

    CPC分类号： A61K31/454 ,  A61K31/00

    摘要： Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

    摘要翻译： 公开了治疗，预防和/或控制中枢神经系统疾病如肌萎缩性侧索硬化症（ALS或Lou Gehrig's disease）及相关综合征的方法。 具体方法包括单独或与第二活性成分组合施用本发明的免疫调节化合物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药。 还公开了适用于本发明方法的药物组合物，单一单位剂型和试剂盒。

    Drug-coated stents and methods of use therefor
    9.
    发明申请
    Drug-coated stents and methods of use therefor 审中-公开
    药物涂层支架及其使用方法

    公开(公告)号：US20050019366A1

    公开(公告)日：2005-01-27

    申请号：US10749344

    申请日：2003-12-30

    申请人： Jerome Zeldis

    发明人： Jerome Zeldis

    IPC分类号： A61K31/415 ,  A61L31/16 ,  A61F2/00

    CPC分类号： A61L31/16 ,  A61K31/415 ,  A61L2300/434

    摘要： This invention relates to stents comprising an effective amount of a c-Jun N-terminal kinase (“JNK”) Inhibitor, the stents being useful for treating or preventing a cardiovascular or renal disease. The invention also relates to the treatment or prevention of cardiovascular or renal disease, such as atherosclerosis or restenosis, comprising implanting into a patient in need thereof of a stent comprising an effective amount of a JNK Inhibitor.

    摘要翻译： 本发明涉及包含有效量的c-Jun N-末端激酶（“JNK”）抑制剂的支架，该支架可用于治疗或预防心血管或肾脏疾病。 本发明还涉及治疗或预防心血管或肾脏疾病，例如动脉粥样硬化或再狭窄，其包括向有需要的患者植入含有有效量的JNK抑制剂的支架。

    Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
    10.
    发明申请
    Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas 审中-公开
    使用3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮处理套细胞淋巴瘤的方法

    公开(公告)号：US20080038263A1

    公开(公告)日：2008-02-14

    申请号：US11888881

    申请日：2007-08-01

    申请人： Jerome Zeldis

    发明人： Jerome Zeldis

    IPC分类号： A61K31/496 ,  A61K39/395 ,  A61P35/00

    CPC分类号： A61K31/454 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/573 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2300/00

    摘要： Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.

    摘要翻译： 公开了治疗，预防或治疗外套细胞淋巴瘤的方法。 所述方法包括施用称为Revlimid或来那度胺的本发明的免疫调节化合物。 本发明还涉及使用该化合物与化学疗法，放射疗法，激素疗法，生物疗法或免疫治疗方法。 还公开了适用于本发明方法的药物组合物和单一单位剂型。